Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Lymphir (denileukin diftitox-cxdl)
i
Other names:
E7777
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
Citius Oncology, Eisai
Drug class:
IL-2 stimulant
Related drugs:
‹
denileukin diftitox (4)
CUE-101 (3)
NKTR-214 (3)
aldesleukin (2)
AVB-001 (1)
AGX-148 (0)
ALT-801 (0)
AWT020 (0)
BNT151 (0)
CLN-617 (0)
CUE-102 (0)
CUG288 (0)
celmoleukin (0)
DI Leu16 IL-2 (0)
GS-4528 (0)
HM16390 (0)
teceleukin (0)
KY1043 (0)
LOAd732 (0)
leukocyte interleukin injection (0)
NL-201 (0)
ODC-IL2 (0)
P-IL-2 (0)
PF-06753512 (0)
PSA/IL-2/GM-CSF vaccine (0)
SHR-1916 (0)
SLC-3010 (0)
STK-009/SYNCAR-001 (0)
attenuated Salmonella typhimurium expressing IL-2 (0)
EMD 521873 (0)
IL2-L19-TNF (0)
WTX-124 (0)
Ax-101 (0)
RG7813 (0)
L19IL2 (0)
RG6279 (0)
AB248 (0)
TILT-123 (0)
AU-007 (0)
STAR-LLD SC (0)
APN301 (0)
TG4010 (0)
SOT101 (0)
SAR444245 (0)
RG7461 (0)
F16-IL2 (0)
TG4001 (0)
denileukin diftitox (4)
CUE-101 (3)
NKTR-214 (3)
aldesleukin (2)
AVB-001 (1)
AGX-148 (0)
ALT-801 (0)
AWT020 (0)
BNT151 (0)
CLN-617 (0)
CUE-102 (0)
CUG288 (0)
celmoleukin (0)
DI Leu16 IL-2 (0)
GS-4528 (0)
HM16390 (0)
teceleukin (0)
KY1043 (0)
LOAd732 (0)
leukocyte interleukin injection (0)
NL-201 (0)
ODC-IL2 (0)
P-IL-2 (0)
PF-06753512 (0)
PSA/IL-2/GM-CSF vaccine (0)
SHR-1916 (0)
SLC-3010 (0)
STK-009/SYNCAR-001 (0)
attenuated Salmonella typhimurium expressing IL-2 (0)
EMD 521873 (0)
IL2-L19-TNF (0)
WTX-124 (0)
Ax-101 (0)
RG7813 (0)
L19IL2 (0)
RG6279 (0)
AB248 (0)
TILT-123 (0)
AU-007 (0)
STAR-LLD SC (0)
APN301 (0)
TG4010 (0)
SOT101 (0)
SAR444245 (0)
RG7461 (0)
F16-IL2 (0)
TG4001 (0)
›
Associations
(1)
News
Trials
Phase
Status
Apply
Phase
Status
Apply
T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors (NCT05200559)
Phase 1/2
Haider Mahdi
Haider Mahdi
Recruiting
Phase 1/2
Haider Mahdi
Recruiting
Last update posted :
11/09/2023
Initiation :
09/30/2022
Primary completion :
12/01/2025
Completion :
12/01/2027
MSI • CD4 • IL2
|
MSI-H/dMMR
|
Keytruda (pembrolizumab) • Lymphir (denileukin diftitox-cxdl)
Study of E7777 Prior to Kymriah for R/R DLBCL (NCT04855253)
Phase 1/2
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Mi...
Recruiting
Phase 1/2
Masonic Cancer Center, University of Minnesota
Recruiting
Last update posted :
07/07/2023
Initiation :
06/09/2021
Primary completion :
12/01/2024
Completion :
12/01/2024
MYC
|
MYC expression
|
Kymriah (tisagenlecleucel-T) • Ontak (denileukin diftitox) • Lymphir (denileukin diftitox-cxdl)
A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma (NCT01871727)
Phase 3
Eisai Inc.
Eisai Inc.
Completed
Phase 3
Eisai Inc.
Completed
Last update posted :
12/12/2022
Initiation :
05/30/2013
Primary completion :
12/06/2021
Completion :
12/14/2021
IL2RA • IL2 • ISG20
|
Ontak (denileukin diftitox) • Lymphir (denileukin diftitox-cxdl)
Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma (NCT02676778)
Phase 2
Eisai Co., Ltd.
Eisai Co., Ltd.
Completed
Phase 2
Eisai Co., Ltd.
Completed
Last update posted :
07/15/2021
Initiation :
03/28/2016
Primary completion :
04/26/2019
Completion :
04/26/2019
IL2
|
Ontak (denileukin diftitox) • Lymphir (denileukin diftitox-cxdl)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login